Danielle Marie Moss, APRN, CNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 112 E Luellen Rd, Hinton, OK 73047 Phone: 405-542-2278 |
Nora Aghasedo, NURSE PRACTITIONER Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: Po Box 1018, Hinton, OK 73047 Phone: 405-542-3711 |
Randalyn Button, CNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 700 Sugar Creek Dr., Hinton, OK 73047 Phone: 405-542-3711 |
Mrs. Brittny Renee Everett, APRN Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 700 Sugar Creek Road, Hinton, OK 73047 Phone: 405-542-3711 |
News Archive
Regenerative medicine using stem cells is an increasingly promising approach to treat many types of injury. Transplanted stem cells can differentiate into just about any other kind of cell, including neurons to potentially reconnect a severed spinal cord and repair paralysis.
Containing costs while delivering high-quality, effective care is a directive of healthcare reform. With episode-based care as part of the reform mandate, many healthcare providers are uncertain about its effect on both patient outcomes and their bottom-line. Toshiba America Medical Systems, Inc. is partnering with leading healthcare providers to develop solutions to address episode-based care by effectively utilizing patient-focused imaging technology and a multidisciplinary collaborative approach to treatment.
Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.
It is estimated that in 2000, more than 359,000 persons were living with a diagnosis of a primary brain tumor in the United States. In 2005, it is estimated that nearly 12,800 deaths will be associated with malignant tumors of the brain and other parts of the central nervous system. Brain tumors are the leading cause of cancer-related deaths in children age 19 and younger.
Genervon scientists have confirmed that the target of GM604 regulates over 4,000 genes. More significantly, it modifies ALS disease progression by modulating at least 30 significant ALS related genes. It does this through at least 8 pathways, potentially more, and up to 22 biological processes.
› Verified 2 days ago